文献速递血栓与止血

抗严重急性呼吸综合征冠状病毒2腺病毒载体疫苗触发亚临床抗血小板自身免疫并增加可溶性血小板活化标志物

Anti-severe acute respiratory syndrome coronavirus-2 adenoviral-vector vaccines trigger subclinical antiplatelet autoimmunity and increase of soluble platelet activation markers.
PubMed 文献 · Br J Haematol · 2022-05-16

该前瞻性研究在健康受试者中评估接种第一剂ChAdOx1、Ad26.COV2.S或BNT162b2疫苗后的血小板特异性及非特异性免疫反应、体内血小板活化及凝血活化。结果显示,接种ChAdOx1者高频出现自身或同种抗血小板抗体,Ad26.COV2.S次之,并伴有循环血小板衍生微囊泡和可溶性P-选择素增加及轻度凝血活化。研究表明,抗SARS-CoV-2疫苗接种者中涉及血小板的免疫反应并不少见,尤其见于ChAdOx1和Ad26.COV2.S接种后,且与体内血小板及凝血活化相关。

要点

  • 接种ChAdOx1者高频出现自身或同种抗血小板抗体,Ad26.COV2.S次之。
  • 上述抗体出现伴随循环血小板衍生微囊泡和可溶性P-选择素增加。
  • 抗体出现与轻度凝血活化相关,尤其在ChAdOx1和Ad26.COV2.S接种后。

核心结论

  • 接种抗SARS-CoV-2疫苗者中涉及血小板的免疫反应并不少见,尤其见于ChAdOx1和Ad26.COV2.S接种后,且与体内血小板及凝血活化相关。

研究设计与样本

  • 前瞻性研究,纳入接种第一剂ChAdOx1或Ad26.COV2.S或BNT162b2疫苗的健康受试者,评估血小板特异性及非特异性免疫反应、体内血小板活化及凝血活化。

主要发现

  • 接种ChAdOx1者高频出现自身或同种抗血小板抗体,Ad26.COV2.S次之。
  • 上述受试者出现循环血小板衍生微囊泡和可溶性P-选择素增加,并伴有轻度凝血活化。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

To slow down the coronavirus disease 2019 (COVID-19) pandemic an unequalled vaccination campaign was initiated. Despite proven efficacy and safety, a rare but potentially fatal complication of adenoviral-vector vaccines, called vaccine-induced immune thrombotic thrombocytopenia (VITT), has emerged the pathogenesis of which seems to be related to the development of platelet-activating anti-platelet factor 4 (PF4) antibodies. While a few studies have evaluated the incidence of anti-PF4 positivity in anti-severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccine recipients, to date no studies have assessed whether an antiplatelet immunological response develops and if this associates with platelet and blood clotting activation. We carried out a prospective study in healthy subjects who received the first dose of ChAdOx1 or Ad26.COV2.S or BNT162b2 vaccines to evaluate platelet-specific and non-specific immune response and in vivo platelet activation and blood clotting activation. Individuals receiving ChAdOx1 and, less so, Ad26.COV2.S developed with high frequency auto- or alloantiplatelet antibodies, increased circulating platelet-derived microvesicles and soluble P-selectin associated with mild blood clotting activation. Our study shows that an immunological reaction involving platelets is not uncommon in individuals receiving anti-SARS-CoV-2 vaccination, especially after ChAdOx1 and Ad26.COV2.S, and that it associates with in vivo platelet and blood clotting activation.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Petito E, Colonna E, Falcinelli E, et al. Anti-severe acute respiratory syndrome coronavirus-2 adenoviral-vector vaccines trigger subclinical antiplatelet autoimmunity and increase of soluble platelet activation markers. Br J Haematol. 2022. PMID: 35577507. doi:10.1111/bjh.18245

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。